Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference23 articles.
1. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C et al (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 29(Suppl 4):192–237
2. El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN et al (2019) Characteristics and outcomes of patients with metastatic kras-mutant lung adenocarcinomas: the lung cancer mutation consortium experience. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 14(5):876–889
3. Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J et al (2017) Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov juin 7(6):596–609
4. Dogan S, Shen R, Ang DC, Johnson ML, D’Angelo SP, Paik PK et al (2012) Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res Off J Am Assoc Cancer Res 18(22):6169–6177
5. Goulding RE, Chenoweth M, Carter GC, Boye ME, Sheffield KM, John WJ et al (2020) KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: a systematic literature review and meta-analysis. Cancer Treat Res Commun 24:100200
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献